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Abstract 
Transcription factors are the major agents that read the regulatory sequence information in the 
genome to initiate changes in expression of specific genes, both in development and in physiological 
activation responses.  Their actions depend on site-specific DNA binding and are largely guided by 
their individual DNA target sequence specificities. However, their action is far more conditional in a 
real developmental context than would be expected for simple reading of local genomic DNA 
sequence, which is common to all cells in the organism. They are constrained by slow-changing 
chromatin states and by interactions with other transcription factors, which affect their occupancy 
patterns of potential sites across the genome.  These mechanisms lead to emergent discontinuities in 
function even for transcription factors with minimally changing expression.  This is well revealed by 
diverse lineages of blood cells developing throughout life from hematopoietic stem cells, which use 
overlapping combinations of transcription factors to drive strongly divergent gene regulation 
programs. Here, using development of T lymphocytes from hematopoietic multipotent progenitor 
cells as a focus, recent evidence is reviewed on how binding specificity and dynamics, transcription 
factor cooperativity, and chromatin state changes impact the effective regulatory functions of key 
transcription factors including PU.1, Runx1, Notch/RBPJ, and Bcl11b.    
Significance Statement 
Transcription factors “read” the genomic sequence to determine when and where gene expression 
should take place. They are vital for sequential developmental changes, and their collaboration in 
different combinations allows gene networks to operate that generate thousands of different cell 
types. However, their mechanisms of action on the genome in stem-cell based mammalian systems 
are based on many additional factors in addition to their ability to bind specifically recognized sites 
in the DNA. Here, the early T-cell development system provides a specific vantage on how 
transcription factors interact with each other and both alter and respond to chromatin states to create 
developmental discontinuities. The different time constants of these effects have a great impact on 












Transcription factors (TF) are the key readers of genomic regulatory sequence, and they bring 
specificity to developmental gene regulation. Unlike other transcriptional regulators, they work (i) in 
trans, (ii) coordinating activities of sites across the genome, and (iii) in a sequence-specific way, 
discriminating one potential regulatory site from another. Combinatorial requirements for concerted 
TF actions underlie the logic operating at nodes of gene regulatory networks. Gene regulation 
mechanisms not only direct development but also mediate the acute physiological responses of 
mature differentiated cells to perturbation (1-4). However, most physiological responses are 
temporary, allowing the cell to return to something very much like the initial ground state after the 
stimulus is removed. By contrast, development forecloses previous regulatory options and opens 
others at each step, causing a permanent change in the ground state.  A central question is how 
different mechanisms interact to generate this irreversibility. 
In an embryo, the overall complexity increase can itself be a source of irreversibility.  Complex 
patterns of transcription factor expression in different cells of the embryo are generated by 
hierarchical gene regulatory network operation, and boundaries between different cell types are often 
direct outcomes of all-or-none differences between the expression of specific transcription factors on 
each side of the future boundary (rev. in (5)). These expression differences are often triggered or 
reinforced by signaling from the neighboring cells as soon as they become distinct, with new signal-
interaction interfaces appearing as cell division proceeds, thus relating gene network progression to 
the increasing anatomical complexity of the embryo. However, hematopoiesis, the best-studied 
example of development from stem cells, is different. In hematopoiesis, progressive changes in cell 
state also occur. However, because each hematopoietic cell’s fate is determined independent of 
others and maintained despite its migration through different microenvironments, these changes 
must be enforced at the single-cell level, where there is no increase in complexity.  The direction of 
developmental change must be based on cell-intrinsic, heritable mechanisms enabling each cell to 
keep track of where it is in a multi-step developmental pathway. Some of these mechanisms are 
evident in sharp shifts in TF site-binding preferences across the genome at specific developmental 
state transitions. As described below, recent evidence shows that even the same TF expressed at 
virtually unchanging levels in one of these lineages can regulate completely different target genes 










The stage discontinuities may help to preserve the directionality of this process. Thus, the question 
of how system irreversibility is achieved can be approached through the mechanisms constraining 
the scope of action of individual TFs in different developmental contexts.  Major candidates for 
these mechanisms are ordered activation or de-activation of collaborating TF activities for joint 
target gene regulation, and/or long-term changes in chromatin accessibility, that transform the 
ground states for gene regulation.  
This article will first review the modes of interaction between TF-based and chromatin states that 
can contribute to gene regulatory logic in the context of differentiating cells in long-lived, complex 
organisms. It will then draw upon highly detailed evidence from the early T-cell developmental 
pathway to consider how distinct biophysical mechanisms may respectively contribute to the 
regulatory logic, kinetics, and irreversibility of developmental progression. The results in this system 
show that we must account not only for different stable cell type identities, but also for the 
mechanisms that can transiently break this stability at key developmental transitions, to shift a 
progenitor to a new, re-stabilized identity in which many old components play new roles. 
 
Binding, detection of binding, and functional association 
Sequence-specific TFs are normally assumed to work through DNA binding and to bind to specific 
sites based on DNA sequence motif recognition (8-11). However, it does not follow that all potential 
target sites are bound by an available TF at a given time, nor that their binding necessarily 
corresponds with function.  This has become clear as in the past 15 years, ChIP-seq (12) and its 
derivatives, ChIP-exo (13) and CUT&RUN (14), have vastly simplified the job of determining where 
on the genome TFs are actually binding at a given moment in a particular cell type. They have 
technical limitations (cell numbers needed) and caveats for interpretation (crosslinking issues, 
possible open-chromatin bias). Nevertheless, these methods have demonstrated two important 
features of the relationship of regulatory genome sequence to TF function, especially in mammalian 
cells: namely, selective, conditional site binding choice and rare functionality.   
First, ChIP-seq data show that many TFs, at least in well-defined mammalian cell types, bind 
detectably to only a small subset of the potential target sequences encoded by the genome. On the 
order of 104 sites are typically found occupied by a given TF, in a genome which should contain 105-
106 equally good copies of their target motifs.  This might be explained on the basis of differential 
affinity and TF expression levels [“fugacity”, (15)](Fig. 1A, top). However, occupancy patterns for 










Second, at the same time, the sites that TFs bind to are far more numerous than are accounted for by 
the genetic loci that actually respond to the presence of those TFs, in gain or loss of function 
perturbations. Typical disparities for the factors described below are ~20,000 binding sites but only 
~500 responsive loci (activated and/or repressed). A particular hotspot for “false” positives can be 
promoters. Strong TF binding is often seen at promoters and apparent open chromatin regions 
around genes that are actively being expressed, whether these genes actually respond to those TFs or 
not. In descriptive whole genome surveys such genes are often assumed to be TF targets, but when 
actual functional tests are done by perturbation of TF levels, most genes linked with TF binding are 
found not to be regulated by the TF in that cell context [for example, (16-20)].  While there are 
several possible explanations, the results emphasize that ChIP-seq evidence for TF binding on its 
own cannot be equated with function.  It regularly occurs at a large excess of “nonfunctional” sites, 
demanding another explanation for what distinguishes the functional ones.   
 
Combinatorial binding stabilization by direct TF-TF interaction 
Genome-wide binding data have raised questions about the degree to which each TF’s recognition 
specificity contributes independently to its own binding profile. Because TFs recognize different 
DNA sequence motifs, in the early 2000’s it was a natural assumption that combinations of TFs 
would only be found binding together at genomic sites where all of them independently recognized 
their cognate motifs; thus, the genome would use the full combinatorial complexity potential of TF 
specificities to encode the requirements for activity at a given enhancer site.  
Different TFs with overlapping, but non-identical, patterns of expression can indeed convey 
independent logical inputs for gene regulation if each depends on the other to stabilize its binding 
(Fig. 1B). At sites where DNA sequence provides weak to moderate matches to each of the target 
motifs, the “AND” logic through which the two factors collaborate for gene regulation can be 
manifest directly through a structural requirement for simultaneous binding. Such AND logic, as 
partner factor expression changes, can clearly provide part of the explanation for stage-specificity of 
TF binding (see below; Runx). Collaborative binding has also been argued to limit the potential of 
each individual TF to bind to developmentally irrelevant regulatory elements (21) in a given context. 
Collaborative mechanisms can be more or less structurally specific. Some TFs have structural 
features that require them to be recruited to a given site by interaction with another specific TF or 
TFs (22). In such cases, the expression of one of these other factors in the cell can make an all-or-










autoinhibitory domain that reduces its own binding to naked DNA. However, this inhibition can be 
removed allosterically by interaction with either Runx1 or Pax5.  In B-lymphoid lineage cells, which 
uniquely express Pax5, this gives Ets1 access to Ets/Pax composite sites that Ets1 cannot bind in 
other cells (23).  In T lineage cells, Ets1 collaborates with Runx1 to bind to composite Ets/Runx 
sites (24-26). In other examples, the interferon-response factor IRF4 shows an ability to form highly 
specific collaborations with the Ets subfamily member PU.1 at composite Ets-IRF elements (27, 28) 
(called “EICE”), while it forms alternative collaborations with basic leucine zipper (bZIP) AP-
1/BATF family members at other composite sites (AICE)(29).  The differential availability of these 
partners in different lineages and under different signaling conditions then effectively changes the 
affinity of the shared factor for different composite sites. Other well-known cases are those of PU.1 
interacting selectively with the basic leucine zipper C/EBP family TFs in myeloid cells, although not 
in B cells (30). Natural single-nucleotide polymorphisms between different mouse strains show that 
the binding of either PU.1 or C/EBP to regions of PU.1 and C/EBP motifs in normal myeloid cells 
depends on the integrity of the motif for the other factor at that site as well as its own (31).  
In initially studied examples, sites for functionally interacting TFs were closely juxtaposed in 
regulatory element DNA (32-36). This could suggest that the genome encodes stereospecific 
requirements for TF combinatorial action. However, evolutionary comparisons have shown that the 
binding site spacings and orders in a regulatory systems can be highly variable, yet still keep the 
target gene similarly responsive to combined action by the same TFs (37, 38).  This makes it likely 
that TF-TF functional collaboration is also favored by mechanisms that do not require such 
structural precision.  
 
Chromatin gating of TF access 
The possibility of a TF’s engaging a given binding site may also be affected by accessibility 
constraints due to local chromatin states, which are a function of the lineage history of the cell type.  
Accurate modeling of the kinetics of TF actions in development depends on taking account of these 
mechanisms, even in fast-developing Drosophila embryos (39), and as described below, their impact 
is likely to be much stronger in slow mammalian systems.  Hints of the power of chromatin 
accessibility to bias TF binding choices have come from ChIP-seq analyses of multiple, structurally 
disparate TFs within the same cell type. While genomic sequence would predict different TFs to 
display completely different binding patterns, about 10 years ago the earliest multi-TF ChIP-seq 










binding deployment (40). When 10 distinct TFs were interrogated, instead of finding 10 unique 
binding profiles with only a few, highly significant sites of overlap, the patterns of binding for many 
of the TFs had unexpectedly high similarities. Among the sites bound were sites that had previously 
been identified as functional enhancers, but a heptad of structurally different TFs binding together to 
the same sites dominated the pattern (41).   
Chromatin compaction can affect TF binding access (Fig. 1A, bottom), and different cell types show 
dramatically distinct patterns of nucleosome packing in chromatin across the genome. These 
patterns have long been detected by nuclease accessibility (42-44) and have recently become much 
easier to detect by accessibility to transposase action (ATAC-seq) (45). Using genome-wide mapping 
of chromatin accessibility, it has commonly been found that the binding patterns of diverse TFs are 
concentrated at “open” sites within the given cell. The question is whether this association is a 
consequence of the TF action, or a constraint upon it.  
Those TFs that can bind their sites even when chromatin appears closed have special roles as 
“pioneer” factors (46, 47)(Fig. 1C, role of “factor B”).  The initial displacement of a nucleosome by a 
stably bound TF can broadly enhance access for others, as long as the site remains open (48)(Fig. 
1C). In at least some cases, such as endodermal pioneering by FoxA1 and lymphomyeloid cell 
pioneering by PU.1 (see below), the role of a pioneer TF indeed correlates with establishment of a 
new, heritable developmental ground state.  
The physical accessibility detected by DNase or transposase is only one parameter of chromatin 
configuration that shows cell type specific differences without being encoded by DNA sequences per 
se, and it is possible that some of these other chromatin features also affect TF access.  Locally, 
nucleosomes can be modified with “active” marks like H3K4 di- and tri-methylation and acetylation 
of H3K9 and H3K27, or “repressive” marks like trimethylation of H3K9 or H3K27. Locally, also, 
methylation of DNA may interfere with a TF’s recognition of its target sites.  At a larger scale, 
chromosomal loci can be sequestered in different nuclear regions in different cell types (49), in 
“active” or “inactive” compartments (50, 51), enclosed in different topologically associated  
domains, and engaged in different local CTCF-anchored loops generated by cohesin-dependent loop 
extrusion (52, 53). All of these chromatin differences that distinguish cell types are regularly 
correlated with differential gene expression in steady state. Furthermore, acute gene induction 
responses, e.g. in immune cells undergoing stimulation by antigens or cytokines, nicely correlate a 
variety of rapid local chromatin changes with changes in gene expression, e.g. local increases in 










chromatin topological changes in mature T cells whenever they get activated by T-cell receptor 
signals (54-56).  
An insight into the mechanisms used to couple TF action to large scale-chromatin change comes 
from the example of a well characterized TF that causes widely-propagated chromatin 
reconfiguration at a key developmental transition in T-cell development (cf. Fig. 1D). At the end of 
the pro-T cell stages (see below), the E protein E2A acts abruptly to open the locus encoding the 
Rag1 and Rag2 transposases that assemble the T-cell antigen receptor genes for expression (57). E2A 
and its paralog HEB are known to be functionally crucial for the expression of the Rag1-Rag2 locus, 
working through a T lineage-specific enhancer element (57, 58). Mutational disruption of seven E2A 
binding sites clustered together within this ~2 kb enhancer in vivo has recently confirmed that E2A 
binding at this relatively compact element is essential for impacts that propagate all across the ~200 
kb topologically associated domain containing the Rag1-Rag2 locus. Binding at this enhancer is 
indispensable to allow loading of cohesin, to flip interaction compartment status from inactive to 
active, and maintain open chromatin structure over this wide region (57). 
 
Chromatin and regulatory dynamics: time and reversibility 
Such chromatin changes could be important to explain the processivity of development if they alter 
the playing field for future gene regulation in the cells, with different time constants than those of TF 
binding itself. Chromatin stage change is usually induced by action of TF combinations (59-66) (Fig. 
1C, D). In addition to the chromatin-opening effects of pioneer factors described above, 
chromosome looping as well as local depositions of active chromatin marks are rapidly increased by 
the activation of signal-dependent TFs like STAT and Notch/RBPJ (2, 4, 67). 
In principle, the time scales of the effects of TF-TF collaboration on open sites and effects of TF-
induced chromatin change could be different.  TF-TF collaboration at accessible sites is immediate 
(Fig. 1B), and at a given site, concerted TF binding per se is memoryless. In contrast, a new pattern 
of chromatin accessibility (or modification, or architecture; Fig. 1C,D) could be inherited, 
perpetuated by default through cell division by reader-writer mechanisms that are sequence-
nonspecific. Such passive propagation of a chromatin state would represent a source of regulatory 
inertia within an established cell lineage, making regulatory baselines dependent on lineage history, 
and resisting change until the statuses of specific loci are disrupted by specific TF combinations, 
either in normal development or in artificial reprogramming (65, 68, 69).  However, the ease of 









which of these mechanisms really are most important to affect future gene regulation. Only a subset 
of these induction-dependent chromatin changes appear to cause lasting changes in regulatory 
thresholds (60, 62).  
Although higher-order chromatin looping is biophysically impressive, its regulatory impact may be 
heterogeneous.  Promoter-enhancer interactions of course occur during transcriptional activity, but it 
is not clear how strongly larger-scale topology affects regulation.  In immune cells, activation-
induced changes in looping do not appear to alter the larger pattern of gene associations between 
active and inactive chromatin compartments (56) and may be largely reversible when the cells revert 
to resting states. Elegant experiments in which cohesin or CTCF was acutely degraded in tissue 
culture cells or in noncycling thymocytes (to filter out confounding population effects due to cohesin 
roles in mitosis) showed that while loss of these components rapidly dissociated loops, a large 
fraction of the cell-type specific gene expression in steady state was independent of the loop structure 
(70-72).   
A better candidate for a long-term threshold-setter for gene regulatory baselines may be DNA CpG 
methylation, which has long been known to be propagated across cell cycles (73). Although not 
strictly correlated with transcription, it has been implicated in long-term shifts in gene expression 
defaults in systems from T helper cell lineage choice to B-cell development to reprogramming of 
differentiated cells to iPS cells (34, 63, 65, 74-78). In a deliberately simplified system, among four 
different repressive mechanisms, DNA methylation gave the most durable response changes (79).  
Not simply a symptom of closed chromatin, target motif methylation also specifically disfavors 
recognition by TFs of multiple families (80). This mechanism is not used in classic developmental 
gene regulatory systems like the Drosophila embryo, though, and it is challenging to monitor in a 
truly genome-wide manner with small cell numbers. These issues have limited the developmental 
contexts in which functional regulatory impacts of methylation have been studied closely to date.  
Still, demethylation of specific sites via TET-dependent oxidation appears to be highly correlated 
with developmental gene regulation in the systems described below (81-85), and some novel 
approaches to manipulate methylation in a targeted way offer huge future promise (86). 
Thus, beyond showing that TFs can affect certain features of chromatin, there is an acute need for 
quantitative measurement of the strengths of these chromatin state effects and the kinetics and 
reversibilities of chromatin state changes, to gauge the extent to which they really cause 
discontinuities in the normal “playing field” for developmental gene regulation.  The relationships of 
both directly collaborative and chromatin state-based mechanisms to modulate TF regulatory 











Hematopoietic development as a distinct window on TF rules of action 
Hematopoiesis is an informative, distinctive system in which to examine cause and effect 
relationships in transcriptional regulation.  Hematopoietic development (after the first cohorts in the 
embryo) begins from “set-aside” cells that are apparently restricted to hematopoietic fates but 
maintain access to ~12 different major fate options. As stem cells, they are mitotically quiescent for 
long periods of time, occasionally carrying out a self-renewal cell division, but are capable of great 
proliferative expansion if triggered.  Individual hematopoietic stem cells become activated rarely and 
asynchronously through life, and then generate large clones of rapidly dividing multipotent 
progenitors with various developmental repertoires, which go on to differentiate along different 
combinations of pathways. Thus, hematopoiesis is a developmental system that generates new 
differentiated cells continuously through the entire lifespan. Fig. 2A presents a simplified roadmap 
of mammalian hematopoiesis and shows some of the key TFs that are essential for major 
differentiation branches. For example, development of red blood cells (erythrocytes) and platelets 
(from megakaryocytes) depends heavily on GATA1 and GATA2 dual-C4 zinc finger factors. 
“Myeloid” innate-immune and inflammatory cells, including monocytes, macrophages, dendritic 
cells, and neutrophils, depend on PU.1 (divergent Ets subfamily). Lymphoid cells of all types depend 
on multi-C2H2 zinc finger factor Ikaros, and B and T lymphocytes in particular depend on basic 
helix-loop-helix E proteins (87-91). (Additional lymphoid-essential factors of the Runx and Bcl11 
families are described in detail below.) This system provides vivid examples to show that individual 
TF roles in the relevant gene regulatory networks are highly conditional, not simply based on 
binding to genomic motifs with the highest possible affinities.   
In classic work, cell fate determination in mammalian hematopoiesis has been explained by simple 
gene regulatory network circuits (90, 92, 93)(e.g., Fig. 2B). Various lineages of descendants are 
distinguished by expression of TF that are expressed in apparently lineage-specific ways (Fig. 2A) 
and show mutual antagonism in experimental tests (Fig. 2B).  Importantly, however, a regulated 
ability to switch network states is inherent to the function of the hematopoietic system. The long-
term stability of the poised state in the stem cells and multipotent precursors is based on the active 
operation of “stem/progenitor” gene regulatory networks (94) which must regularly get overridden 
when the cells commit to differentiate.  Despite the association of key TFs with different, mutually 
exclusive pathways of differentiation, the hematopoietic precursors start out with overlapping 
expression of these same TFs, which can play roles both in the “stem/progenitor” network and in 










each other in a mutual-exclusivity gene regulatory network circuit in one cell type can collaborate in 
another (100-102). In part, this is because the same TFs collaborate with different, independently 
regulated TFs when they participate in different developmental programs. Examples are GATA 
family factors and the Ets-family factor PU.1 (92, 103-105). GATA1 opposes PU.1 in erythrocyte vs. 
monocyte/macrophage specification, mutually repressing each other and mutually inhibiting each 
other’s transcriptional regulatory activities (Fig. 2B). However, these two factors collaborate in mast 
cell development and function (106). The highly stable mast-cell state is apparently made possible by 
the absence of certain partners of PU.1 and GATA1, C/EBPα and FOG1, respectively (93, 102, 
107)(Fig. 2C). Thus, because of availability of different partners, the logic relating a given TF’s 
action to a particular target gene’s expression is dependent on the cell lineage (101, 108).  
There is conditionality also in the dose dependence of factor action in hematopoiesis. PU.1 at high 
levels blocks B cell development to favor macrophage development instead (109, 110), whereas PU.1 
at low levels is vital for most B-cell precursors to be produced at all (111, 112). GATA3 is 
indispensable for T cell generation at multiple successive steps, but modest overexpression of 
GATA3 is profoundly inhibitory to the T cell pathway (113-117). Twofold differences count: many 
hematopoietic TFs show haploinsufficiency phenotypes, as reviewed elsewhere (87). A key question 
is whether this high dose sensitivity comes from highly cooperative DNA binding, from competitive 
TF-TF interactions, or from other mechanisms, described below. 
Hematopoiesis thus offers a gallery of distinct contexts in which to examine closely why a given TF 
behaves differently in different contexts within any desired degree of developmental relatedness. 
Different roles can be related directly to different levels of expression, different binding partners, 
and/or different inherited chromatin states. Furthermore, where a precursor-product series has been 
defined, it is possible to test which modifiers of TF action are heritable from stage to stage and which 
act reversibly. Early T cell development is a good case. 
 
Cellular and chromatin contexts of early T cell development 
The steps through which the hematopoietic stem/progenitor gene regulatory network gets 
reconfigured into a committed cell-type gene regulatory network are most readily tracked in the T-
lymphocyte developmental pathway. Multipotent precursors normally undergo this program in the 
thymus, but there are excellent in vitro differentiation systems that reproduce the T-lineage 
commitment process with high efficiency, and fine-scale distinctions among the successive 










component steps in the process to be dissected at unusually high resolution, with clear definition of 
the transition from multipotentiality to commitment at the single-cell level. Main features of the 
pathway are briefly summarized here (for more detail, see (118-122)). 
Upon arrival in the thymus, multipotent precursors are guided into the T cell pathway by multiple 
days of exposure to strong Notch pathway signals (118, 123)(Fig. 3A).  Notch signaling 
simultaneously inhibits the cells from taking alternative, non-T developmental pathways and 
stepwise drives the T-cell specification program forward. In the process, over a dozen transcriptional 
regulators that the multipotent cells had been expressing upon entering the thymus are silenced, 
while new regulatory genes encoding signature TFs of the T-cell program are gradually upregulated.  
Whereas the cells entering the thymus are initially multipotent, through this process they 
intrinsically lose competence for alternative developmental fates, thus undergoing commitment. 
Soon after, they become eligible to rearrange their T-cell receptor (TCR) genes in the distinctive 
recombination and somatic mutation process that ends up giving each cell a unique immune-
receptor specificity, important for its future immune-system roles (124, 125).  However, cell identity 
and commitment are established before TCR gene assembly, in the “pro-T cell” stages.   
This process is notably slow. In the young postnatal mouse thymus, precursors undergo at least 7-10 
cell divisions under the influence of Notch signaling before crossing the transition linked to T-cell 
commitment (126-128). In young postnatal mice, individual stage transitions along the way each 
take ~2 days (2-4 cell cycles) apiece, not hours or minutes (126).  While these pro-T cells 
undoubtedly undergo stochastic transcriptional bursting at active loci like other cells, the slowness of 
the global state changes during their differentiation is an important indicator that the developmental 
impacts of these transcriptional bursts are mostly being buffered. The duration of each substage 
indicates regulatory metastability across multiple cell cycles. This, then, increases the distinctiveness 
of the specific transitions that occur when cells do make a sharp state change. It is the programmed 
alternation between metastable and transition phases that requires explanation. 
At a molecular level, commitment is marked not only by TF expression changes but also by multiple 
coordinated chromatin changes.  T cell precursors before commitment have chromatin accessibility 
profiles, chromatin looping profiles, and chromatin A/B compartment profiles that strikingly 
resemble those of hematopoietic stem cells and multipotent progenitors (129, 130). Then, after 
multiple cell cycles, these profiles change rather sharply to resemble typical T-lineage profiles, and 
the watershed of the most pronounced changes is at the commitment transition itself (129).  By 
following a few key TFs, the impacts of these changes can be seen, and also how the activities of 










Key transcription factors in early T cell development 
The TF-coding genes across the genome that change expression during commitment have been fully 
surveyed (130-132), and several with prominent roles have been subjected to years of genetic and 
molecular analysis. Seven TFs that contribute importantly to the T-cell specification pathway are: 
the progenitor-specific factor PU.1 (an Ets family factor of a distinctive subgroup), the stably 
expressed factors E2A (a basic helix-loop-helix factor), Ikaros (a multi-C2H2 Zn finger factor), and 
Runx1 (a Runt domain factor), and specifically T-lineage associated factors TCF1 (encoded by Tcf7; 
a high mobility group factor), GATA3 (a dual-C4 Zn-finger factor), and Bcl11b (another multi-C2H2 
Zn finger factor).  The expression of these regulatory factors is highly stereotyped and has an 
important period of overlap during the lineage commitment decision (Fig. 3B)(118, 123).  In 
addition, Notch1 and initially also Notch2 with their TF partner RBPJ (also called CSL: CBF-
1/Suppressor of Hairless/Lag-1) provide crucial inputs (6, 133-137). The roles of several of these 
TFs correspond to their developmental expression patterns, with PU.1 governing genes that are 
expressed mostly in multipotent progenitors (19), TCF1 promoting a T-lineage-specific chromatin 
state (138), and TCF1 and Bcl11b active in T-lineage specific gene expression (16, 139-141). 
GATA3, Runx1, Notch/RBPJ, basic helix-loop-helix E proteins, and Ikaros work broadly 
throughout this process, with distinctive and indispensable T-cell roles (6, 7, 113, 114, 142-144). 
However, the functions of the stably expressed TFs are much more dynamic than their seemingly 
flat, unchanging expression patterns would suggest.  Stably expressed factors in this system, such as 
Runx1 and E2A, and Notch signaling repeated across different stages, can all exert notably stage-
specific effects. This stage-specific action of continuously available factors means that these TFs offer 
important points of entry to the mechanisms creating developmental discontinuity. 
Of these factors, the relationships of binding to function have been investigated most deeply for 
PU.1, Bcl11b, and Runx1 in the context of the T-cell commitment process.  PU.1 is expressed 
robustly until commitment, when it is turned off.  Bcl11b is silent in hematopoietic progenitors and 
nearly all non-T hematopoietic cells, and turns on only at T-lineage commitment, but then remains 
on permanently afterwards.  Runx1 is highly expressed in T lineage cells, at similar levels before and 
after commitment, and is expressed more strongly in early T lineage cells than in any other major 
hematopoietic cell type (130). All of these factors are functionally important for T cell development 
(7, 145-151), but each of these factors behaves differently from the others as a molecular agent 










Binding and access rules: PU.1  
PU.1 has been studied extensively in myeloid cells, dendritic cells, and B cells, with deep analyses of 
its binding requirements, pioneering activity, preferred TF activity partners, and dose-dependent 
functions (30, 98, 152-161).  In early T lineage cells, its role is confined to the multipotent, 
precommitment stages. It appears to act primarily as a positive regulator of most of its direct targets 
(genes responding functionally when it binds de novo to linked sites) and as a marker for open 
chromatin sites during the stages when it is expressed (19), binding >30,000 sites in pro-T cells 
before commitment (131).  As the cells undergo commitment it is silenced, and then most T cells 
never express it again. However, it is functionally important for establishing the T-cell precursor pool 
(146).  PU.1 can block Notch signaling if expressed too highly (108), which can result in trans-
differentiation to a myeloid pathway (162, 163), but at normal levels it promotes early T-lineage 
proliferation and protects the cells from deviation to the NK cell pathway (146).  Its target motif is 
consistently seen to be the most enriched motif among chromatin sites that are open specifically 
before commitment (7, 129, 130, 138).   
PU.1 is a biophysically “well-behaved” TF that shows motif-faithful in vivo binding behavior that is 
overall consistent with its in vitro DNA binding activity (19, 152).  Even as its expression declines 
during pro-T cell commitment, it maintains binding to a consistent pattern of sites, albeit with 
declining occupancy, and the sites occupied longest as PU.1 concentration drops are those with 
stronger matches to the PU.1 motif position weight matrix (PWM), as would be predicted by mass 
action (Fig. 3C).  It also acts as a pioneer factor in early T lineage cells, with the ability to locate and 
bind to many of its physiological target sites whether in open or certain kinds of closed chromatin, 
provided that the sites are high affinity (Fig. 3C). This activity can be seen if exogenous PU.1 is 
added (back) to immature T-lineage cells after they have undergone commitment and shut off their 
endogenous PU.1, and when the normal target sites of PU.1 have become closed (19).  Such 
“restored” PU.1 appears to be capable of (re-)opening a large subset of these sites by nucleosome 
displacement (48, 164) and recruiting histone acetyltransferases (19).  PU.1’s pioneering roles in vivo 
are helped by its structural features enabling it to bind sites even in methylated DNA regions (165), 
and by its ability to recruit either DNA methyltransferases or TET enzymes for DNA demethylation 
to its binding sites in different contexts (83).  The genes in pro-T cells that respond most sensitively 
to PU.1 do not necessarily bind PU.1 at their promoters, but rather at distal or intronic sites where 
chromatin opening also depends on PU.1 (19). Thus, PU.1 appears to work in this system as a 










Genome-wide, its binding pattern is a major determinant of the overall pattern of open chromatin 
through the earliest stages of T cell development, which is maintained as long as PU.1 is present (19, 
146). Nevertheless, its ability to engage closed chromatin sites as well depends not only on its DNA 
binding domain but also on the integrity of its non-DNA-binding, protein-interaction domains (19), 
even when the sites have very high-quality binding motifs. These are unstructured domains (166) 
which are likely to promote noncovalent protein condensation and liquid-liquid phase separation, 
very similar to the domain in a B-cell pioneer factor, EBF1, also recently shown to be required for its 
chromatin opening activity (167, 168). This supports evidence from other systems that pioneering 
may often depend on protein-protein cooperation (169).  In the context of non-T hematopoietic cell 
types, PU.1 associates strongly with Interferon Response Factors 4 and 8, NF-κB, and LXR, and has 
especially prominent partnerships involving C/EBP and AP-1 bZIP family factors in myeloid cells 
(27, 28, 30, 31, 157), all of which have motifs co-enriched with PU.1 occupancy sites in myeloid 
cells. However, in pro-T cells, PU.1 interacts preferentially with Runx factors, and the most 
commonly co-enriched motif at PU.1 sites in pro-T cells is a Runx motif (19, 170).  
In summary, PU.1 responds to lineage-specific availabilities of partner factors to establish 
moderately lineage-specific patterns of site choice, but many of its pro-T cell functional target genes 
are in fact regulated similarly by it in other lineages as well (171). Rather than responding sensitively 
to regulatory discontinuities, its own developmental silencing creates regulatory discontinuities. 
 
Binding and access rules: Bcl11b  
Bcl11b is a bifunctional TF, expressed in a reciprocal pattern to that of PU.1, encoded by a gene that 
only becomes transcriptionally active as pro-T cells undergo commitment (172). Bcl11b is important 
for commitment itself as well as for later T-cell functional regulation, with a specific role in blocking 
aberrant activation and effector-differentiation processes of the T cells as well as licensing genes for 
expression that encode crucial T-cell signaling molecules (16, 139, 147-149, 173).  Like PU.1 in 
earlier stages, it binds ~20,000-30,000 sites across the genome in newly-committed pro-T cells and 
often engages sites that are open and associated with active enhancer histone modifications (16, 129, 
139).  The relationship between its binding and function is less clearcut than for PU.1, however.  
More Bcl11b-bound responsive targets appear to be negatively regulated by Bcl11b than positively 
regulated, and Bcl11b forms particularly common interactions with NuRD chromatin remodeling 
complexes, which are often associated with repression (Fig. 3D).  However, Bcl11b binding has also 










rich regions, and loop density usually correlates most with positive regulation (129) (Fig. 3D). 
Although Bcl11b deletion blocks T-cell developmental progression past commitment, acute deletion 
of Bcl11b in mature T cells measurably reduces the number of loops involving sites with at least one 
Bcl11b-associated anchor (129).  Thus, Bcl11b appears to have a role in chromatin architecture, 
distinct from but complementary to that of PU.1.   
The site choice biochemistry of Bcl11b in vivo poses a stark contrast to that of PU.1.  In early T-
lineage cells, Bcl11b’s own DNA binding specificity appears to be substantially masked by its 
interactions with other proteins.  Several studies have identified GC-rich DNA sequence motifs that 
are bound efficiently by Bcl11b with purified DNA in vitro (174, 175). However, these motifs are not 
well-enriched in pro-T cells at the sites where Bcl11b is detected to bind in vivo, nor in the vicinity of 
genes that respond to Bcl11b functionally (16).  Instead, in pro-T cells and later T cells alike, Bcl11b 
is found binding to sites most highly enriched for Runx and Ets-family target motifs (16, 129, 139, 
176, 177), and its occupancy is usually accompanied by detection of Runx1 protein at the same sites 
(7, 16)(Fig. 3D). In many cases, Bcl11b could be binding DNA indirectly, possibly via Runx1. 
However, functionally responsive Bcl11b-regulated targets are enriched for linkage to the minority of 
Bcl11b occupancy sites where Runx1 recruitment or site choice depends on the presence of Bcl11b 
as a binding partner (16). Bcl11b function is thus connected with the subset of its sites where it is 
needed to nucleate assemblies of complexes with Runx1 and chromatin remodeling factors. 
Bcl11b thus creates a novel regulatory state potential with its sudden advent during commitment. 
However, the effect of this new regulatory state is focused less on genes with Bcl11b-specific sites 
than on genes where Bcl11b action can alter the impact of other factors. 
 
Binding and access rules: Runx factors 
Runx family factors are bifunctional and play diverse roles, critical for early hematopoiesis and 
indispensable for T-cell development (178, 179). When Runx1 is first expressed in early 
hematopoiesis, it has the capacity to drive reorganization of the binding of other TFs to establish the 
hematopoietic progenitor state (180, 181). In that context, it has provided a paradigm of how hit-
and-run action can create lasting effects via chromatin alterations (182). Runx factors are also 
expressed very robustly in all stages of the development of precursors into committed pro-T cells, 
enabling them to work both as common partners for PU.1 at open chromatin sites before 
commitment and as common partners for Bcl11b after commitment.  The expression of individual 










most prominent family member after commitment, but the changes in one factor are largely 
balanced by reciprocal changes in another Runx family member so that the total RNA, protein, and 
ChIP-seq-inferred binding activity levels appear almost unchanging (7).   
These factors are of extreme interest despite their stable expression.  First, Runx factors collectively 
are essential for cells to enter and progress through the T-cell program (150, 151). Second, open 
chromatin sites in pro-T cells both before and after commitment are strikingly rich in Runx target 
motifs, whether the sites are opening or closing (7). Runx motifs are accordingly co-enriched at 
functional binding sites of numerous other lymphoid TFs, especially both PU.1 and Bcl11b sites (16, 
19), as noted above in pro-T cells, and at sites for lineage-determining factors E2A and EBF1 in pro-
B cells (183, 184).  Third, the genes that Runx factors regulate positively include many of the 
signature genes of the T-cell program, while the genes that they regulate negatively are involved in 
progenitor states and developmental alternatives (7). Thus, they are critically implicated at the core 
of the T-cell program. 
Binding site choice for Runx factors is superficially conventional. Before, during, and after 
commitment, Runx factors are found binding to sites that are enriched for Runx motifs. 
Interestingly, they are almost equally enriched for motifs for Ets family TFs, PU.1 before 
commitment and Ets1/Erg type after commitment (7). However, in contrast to PU.1, the hierarchy 
of Runx1 binding strengths in vivo does not match the PWM log-odds scores of the individual sites 
(170). In further contrast to PU.1, which remains bound to a similar choice of sites even as its 
concentration drops, Runx binding site choices shift considerably within the T cell lineage as the 
cells go through commitment, even though Runx activity levels stay the same (Fig. 3E). In fact, most 
of the 25,000-30,000 non-promoter sites that Runx factors bind before and after commitment are 
different, with about 1/3 of the total sites abandoned and 1/3 of the sites newly gained as the cells 
progress through commitment (7).  Thus, even at constant levels in the nucleus, Runx occupancy 
choices appear to be strongly affected by shifts in regulatory “context”.  
Runx factors thus provide an ideal readout and probe for the mechanisms transforming the 
regulatory contexts in these two states, just a few days apart in cells of the same lineage. They 
feature strongly in mechanistic insights about system behavior in early T-cell development. 
 










Runx factors provide a glimpse of the mechanisms that may also account for stage-specific actions of 
other non-stage-specific factors.  In early T cell development, Runx factors have sharp, highly stage-
specific impacts on gene expression (7). First, despite their constant levels, they preferentially 
activate or repress the minority of expressed genes that undergo great changes in expression during 
commitment, either positively or negatively (7). Even more surprisingly, their effects on the same 
target genes, whether positive or negative, can change dramatically before and after commitment. 
Many genes dependent on Runx (or repressed by Runx) before commitment are completely 
insensitive to Runx factors after commitment, and many genes regulated by Runx after commitment 
are completely insensitive to Runx factors before commitment.  Thus, not only target choice but also 
the nature of impact are altered by the changes in regulatory state.   
Besides Runx1, Notch signaling itself, E2A, and Ikaros also show evidence for highly stage-specific 
roles in gene expression.  The range of actions of these factors could be guessed in some cases from 
the developmental patterns of expression of the genes they affect (57, 133, 142, 143, 185). However, 
the abruptness of such changes in function has been most fully demonstrated through recent Cas9-
based experimental methods for carrying out the same knockout perturbation in pro-T cells at 
distinct, successive developmental stages (6, 7); for the cleanest results, Cas9-mediated gene 
disruption acutely knocked out redundant paralogs simultaneously to eliminate compensation (6, 7).  
Although Notch is the most important environmental signal driving cells through pro-T 
developmental progression both before and after commitment, the transcriptional responses to 
signaling by the Notch pathway were found to be acutely stage-dependent, as for Runx factors. Most 
genes significantly regulated by Notch signaling (and Notch/RBPJ activity) before commitment 
were not detectably regulated by Notch signaling after commitment at all, and vice versa (6).   
Such results of direct comparisons show that TF-target gene functional regulatory connections need 
to be analyzed in the relevant stage and cannot be assumed to be constant, even within the same cell 
lineage. Furthermore, expression of the regulating TF in these cases is a prerequisite, but is not 
correlated with expression of the target gene, nor with the window of time in which the target is 
sensitive to the regulator. 
 
Stage specificity via TF collaboration and via partner TF competition 
In pro-T cells, Runx factors are highly subject to partner effects.  Before commitment, PU.1 is its 
preferred partner, but the relationship is unequal, as already noted. The binding of PU.1 appears not 










(19) However, the addition of PU.1 to a post-commitment pro-T cell (to drive development 
“backwards”) markedly shifts the occupancy pattern of Runx1 to favor sites where it could co-bind 
with PU.1, abandoning many post-commitment specific sites (170). The PU.1/Runx1 co-bound sites 
often show very weak versions of a Runx PWM, even when they are occupied at the expense of 
seemingly better sites for Runx (“cofactor theft”)(170)(Fig. 4A).  The poor quality of Runx motifs at 
these co-binding sites is a likely symptom of recruitment by protein-protein interactions rather than 
by pure DNA recognition, and is also typical of many Runx sites in the unperturbed cells that 
naturally express PU.1 before commitment.  Conversely, PU.1 co-binding sites are enriched among 
the sites that Runx abandons normally after commitment, when PU.1 is no longer present (7). Thus, 
PU.1 is one of the partners that strongly influences the target site choices that Runx makes.  
After commitment, Runx1 binds most frequently with Bcl11b, although this overlap may be 
somewhat exaggerated by the fixation conditions used to score both factors. The mutual 
dependences have not been examined in both directions, but only a small fraction of Runx binding 
sites appear to depend on the presence of Bcl11b. Interestingly, though, if Bcl11b is deleted, Runx1 
binding then appears at numerous new sites, again of comparable or better enrichment for the 
Runx1 PWM (16). Thus, Bcl11b after commitment is also involved in redirection of some Runx 
binding behavior, though not as dominantly as PU.1 before commitment. Motif analysis at 
developmentally shifting sites (7) suggests possible sites of Runx1 recruitment by E proteins, as well. 
The notable point is not just that one TF can strongly recruit another TF to its binding sites; it is 
rather that this occurs at the expense of a discrete subset of alternative occupancy sites. The result 
suggests that TF partners compete for a functionally limited pool of Runx1 (or other TFs subject to 
“theft” as well), with collateral impacts on many sites without their being bound by the perturbing 
partner TF at all (170). How often this site occupancy shift alters expression of target genes needs 
further investigation. Many genes that are functionally responsive targets of these TFs are 
surrounded with multiple sites of TF binding, spread over tens or hundreds of kb, only some of 
which may be subject to these redirection/ cooperative recruitment effects, interspersed with others 
that remain unaffected (16, 170).  However, even if TF-TF collaboration may only affect an 
interspersed subset of binding sites for each partner, it may play a greater role in longer-scale 
collective effects on chromatin structure, discussed next. 
 










Hit-and-run developmental regulation is a particularly important variant of stage-specific TF 
activity. If TF expression were always correlated with expression of the TF’s target genes, then 
lineages would require stable expression of a core of mutually sustaining, “identity-promoting” TFs.  
For example, macrophages (a major myeloid hematopoietic cell type) do appear to maintain high 
expression of PU.1 as a cell type identifier, whatever their other functional specializations, and this 
plays both a gene network role and a biochemical role as a pioneer factor for macrophage-specific 
cis-regulatory elements (156). However, T lineage cells are unusually long-lived and become 
extremely diversified once mature, and some of the most important lineage-specific TFs activated 
during the T-cell specification program, including TCF1, GATA3, and E2A, can be downregulated 
in particular, specialized T-cell descendants (132). The crucial Notch/RBPJ complex, for example, 
ceases to be essential shortly after the expression of the first version of the T-cell receptor complex 
(186).  Even so, important target genes that initially depend upon these TFs for their activation 
during T cell specification continue to be expressed in a sustained way throughout later mature T-
cell activity states even when these TFs are gone. 
Specific genes regulated by Bcl11b, Notch/RBPJ, and Runx factors during commitment in hit-and-
run fashion show that the same target gene can switch from acute dependence on a regulator to near-
complete independence within days.  Genes of the Cd3 complex, which encode the signaling 
machinery for the T-cell receptor complex, are highly dependent on Bcl11b activity for their initial 
activation in pro-T cells, but become independent of Bcl11b by later stages of T-cell development 
and in mature T cells (16, 139, 148, 187, 188). As already noted, Runx factor activities show 
numerous cases of hit-and-run function, not only in the T-cell lineage (7) but also in establishing the 
progenitor-cell phenotypes at the embryonic origins of definitive hematopoiesis (182).  The gene 
Tcf7, encoding the essential TF TCF1, itself depends intensely on both Notch/RBPJ and Runx 
activity for its expression before commitment, but becomes completely insensitive to changes in 
Notch and Runx activity after commitment (6, 7). Finally, Bcl11b itself is also regulated by hit-and-
run mechanisms.  Despite a strong dependence on Notch signaling to support its eligibility to be 
activated, Bcl11b becomes completely Notch-independent almost immediately once it is expressed 
(172). Also, it is only turned on if TCF1 and GATA3 are active during the earliest pro-T cell stage; 
but it can still be turned on normally if either of these factors is deleted a few days later, yet also 
before Bcl11b turns on (172). Thus, the activating role of TCF1 and GATA3 is required, but can be 
temporally uncoupled from Bcl11b transcriptional initiation in this system almost completely. This is 









These examples emphasize that in these slow-kinetic developmental systems, requirements for TF 
activity are highest in order to trigger changes in gene expression state, not necessarily to maintain 
them.  This is a very different role than to sustain a given rate of RNA polymerase II recruitment 
and transcriptional bursting from a given promoter. While in some cases such hit-and-run behavior 
could be due to a TF role “relay race”, as suggested for some mature T cell responses (60), it could 
also be mediated by durable chromatin state changes. This demands a focused examination of the 
mechanisms involved in creating these discontinuities in gene expression. 
 
Differential impacts of chromatin states on TF binding 
As discussed earlier, many TFs cannot gain access to their binding sites in closed chromatin until 
other “pioneer” factors have opened the chromatin, or at least have established a beachhead (39, 47, 
190, 191). For TFs to open closed chromatin, combinatorial action may be required (169, 192).  
However, different TFs appear to be restricted by qualitatively different chromatin state constraints.  
PU.1 binds to many target sites in closed as well as open chromatin (19, 152), with half of its 
observed binding sites in pro-T cells appearing “closed” by ATAC-seq criteria (19). These “closed” 
binding sites provide evidence for the energetic cost that it pays for establishing occupancy in these 
more restricted regions (19, 152). In pro-T cells, the PU.1 occupancy sites in closed regions have an 
extremely high enrichment of classic PU.1 target motifs and are skewed to higher-quality position 
weight matrix matches with those motifs than its binding sites in open regions (Fig. 3C). The 
differences increase as PU.1 levels in the cell decrease, by log-odds differences of 1.0-1.5 (19), 
corresponding to KD differences from ca. 0.5 µM to 0.2 µM (152).  This higher apparent affinity 
threshold, plus the requirement for non-DNA binding domains that may enable PU.1 to interact 
with other proteins (19), suggest the minimum cost of overcoming the ATAC-closed barrier. 
Polycomb repression complex 2-modified chromatin presents a different kind of barrier. PU.1 
binding appears to be virtually excluded from H3K27me3-modified chromatin sites, both for 
endogenously expressed PU.1 at its natural levels and for PU.1 experimentally re-introduced in later 
T-cell stages, after endogenous PU.1 is turned off (19, 131).  In contrast, GATA3, which is otherwise 
far less robust in its measured site-binding preferences (131, 193), readily binds to certain sites even 
when they are within regions of strong H3K27me3 marking. Thus, polycomb-“repressed” as 
opposed to simply “non-open” chromatin sites may provide a stronger barrier for PU.1 action than 










Although a frequent partner of PU.1, Runx1 observes different chromatin state restrictions.  A 
striking example is seen at a distal enhancer for the Bcl11b locus, where the chromatin is generally 
closed before commitment and open afterwards (Fig. 4B). Runx1, like GATA3, TCF1, and Notch, 
is a functionally important positive regulator of Bcl11b expression, needed for Bcl11b activation (7, 
172). The distal Bcl11b enhancer harbors a cluster of PU.1 sites and Runx sites, which are strongly 
occupied by PU.1 before commitment and by Runx1 after commitment. However, while PU.1 can 
freely bind this enhancer in its “closed” state before commitment (131, 194), Runx factor binding is 
harshly excluded (Fig. 4B). In fact, ChIP-seq profiles show a stark inability of Runx factors to bind 
across almost 2 Mb around the distal enhancer, before commitment. Then, during commitment, 
Runx binding suddenly appears at >30 occupancy sites across this domain (7)(Fig. 4B). At the same 
time, the region undergoes a compartment flip, chromatin looping to the Bcl11b gene body greatly 
increases across the whole 2-Mb interval (129), and Bcl11b is turned on.  
These distinctions show that “closed” chromatin is not a monolithic state, but is perceived 
differently by different transcription factors. Thus, developmental changes in particular aspects of 
chromatin state can cause selective discontinuities in access of particular TFs to the affected genomic 
loci.  
 
Chromatin state inertia can exert substantial kinetic drag on TF response manifestation 
As argued above, TFs can have a long-term, durable impact on gene expression if they trigger 
alterations in local chromatin state, for example, by flipping chromatin at a key regulatory locus 
from “repressed” to “active” and/or by altering DNA methylation.  However, the requirement for 
an extensive chromatin state change can delay the transcriptional response substantially, indeed 
affecting the kinetics of developmental progression (128).  Thus, despite the durability of the effect, 
the response may not appear with tight temporal coupling to the timing of action of the TFs 
themselves.   
In this system, in fact, local chromatin state can provide an “inertial” drag that can delay gene 
expression responses to TFs for days, lagging through multiple cell cycles.  A particularly clear 
example is provided by the kinetics of activation of the two alleles of Bcl11b itself (Fig. 4C). The 
allelic comparison discriminates between effects mediated by trans-acting TFs and effects mediated 
by cis-acting chromatin states. Clearly neither allele would be expected to be active until requisite 
positive regulators were present and negative regulators were removed, but the activation of one 










Tagging of the two alleles of the Bcl11b gene with different fluorescent reporters (without affecting 
the coding function) showed that the two alleles can undergo activation noncoordinately at 
disparate, stochastically distributed times within the same cells (195). This was not due to 
maternal/paternal imprinting, because the alleles turned on in random order among different pro-T 
cells from the same mouse. In cells purified based on their activation of one allele and then followed 
over time, the other allele showed very variable activation timing from one clone to the next, with 
delays ranging up to 4 days (195).  Because TFs rapidly bind and dissociate from DNA over time 
scales that are orders of magnitude shorter than this, there would be no basis for one allele to be 
activated by trans-acting TFs in a cell and its descendants up to 7 cell cycles before the other. Thus, a 
cis-acting mechanism must be part of the brake on activation, delaying it beyond any gene network 
delays in activating the initiating TFs.   
In the case of Bcl11b, several cis-acting mechanisms could be involved. Polycomb complex 2-
modified chromatin (H3K27me3) on some Bcl11b regulatory elements or DNA methylation could 
contribute to the initial deep silencing (194, 196). In addition, Bcl11b is initially sequestered at the 
nuclear periphery from which it shifts to the nuclear interior around the time that it is activated (196, 
197). This relocalization is least partly under control of a cis-acting lncRNA called “thymoD” that is 
crucial for Bcl11b activation (197) and must be transcribed from the vicinity of the key distal 
enhancer (194, 195).  It is unclear how general an example Bcl11b may be: it may be subject to 
special mechanisms making Bcl11b expression particularly hard to induce, but easy to maintain.  
However, this identification of a durable cis-acting constraint depended on comparing activation of 
individual alleles within the same cells, which has not been attempted at many loci. Conceivably, 
such a mechanism could cause stochastic delays to activation timing of many other developmentally 
activated loci as well.   
 
Concluding remarks 
Transcription factors guide a rapidly unfolding cascade of transcriptional change, with remarkably 
coordinated kinetics, in embryonic life. In contrast, in development of individual lymphocytes from 
hematopoietic stem cells in mammals, developmental progression is slow compared to cell cycle 
rate, fate choices have a strong stochastic component, timing is highly variable among cells even 
within the same clone, and cells establish their own differentiation programs independent of the 
choices made in parallel by other cells in the cohort. A question has been how such a “lone wolf” 










binding which is biochemically transient and reversible.  This article suggests that it could draw 
some of its irreversibility from the same chromatin-associated mechanisms that provide “inertial 
drag” to make the progression so slow. Further, the suggestion is that chromatin state change 
dynamics as well as system-level effects of TFs on the activities of their partner TFs together provide 
a controllable switch between stages when the cells’ transcriptional identity is relatively stable and 
self-renewing to stages of rapid change, followed by new stages of metastability that are irreversibly 
different from the preceding ones. 
It is well understood that TFs interact with chromatin mechanisms, but most of the work on this 
area has focused on fully differentiated, immortalized cell lines on the one hand, where gene 
regulation is only measured in a “maintenance” mode, or else on the highly abnormal process of 
lineage erasure and reprogramming caused by forced ectopic expression of a full set of “Yamanaka 
factors”.  The relationships of these identity-deconstruction processes to natural development have 
not been well established.  Here, therefore, the progression of normal T-cell precursors from 
multipotency to T-lineage commitment is proposed as an instructive model in which the constraints 
of TF activity by prior chromatin states can be measured and the impacts of TF activity to cause 
chromatin states to change can be illustrated, tracked and dissected. 
The work reviewed here identifies several features of these real developmental events that are 
important to consider in future modeling of TF action for developmental gene regulation. First, 
binding site choices are highly conditional, based on inherited chromatin state and current 
availabilities of collaborating factors, not simply predictable from genomically encoded site affinities 
and total TF pools in the nucleus. Second, partner interactions compete for functionally limited TF 
pool sizes, causing some indirect effects by depleting particular sites of occupancy to give preference 
to others. The rules that define such “theft”-vulnerable sites and their functional significance need to 
be defined. Third, TF regulatory action can be much more stage specific than TF expression, 
breaking the promise of correlation between responsible TF and responding target genes.  Finally, 
while some TF actions can rapidly cause changes in chromatin looping or histone modification, 
other developmental changes may require extended times to modify cis-acting chromatin states, 
which in some cases may completely uncouple the timing of TF action from response of its target. 
These features offer fascinating glimpses of new aspects of gene regulation that must be taken into 
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Figure 1.  Modulators of transcription factor (TF) binding.   
(A) Affinity and accessibility: comparison of binding of a generic TF “factor A” (magenta triangles) 
of TF affinity for target sites in open and closed chromatin.  Two conditions are shown: occupancy 
in the presence of high levels of factor A, or in the presence of low factor A. Blue shading of sites 
indicates relative site affinities as shown in key.  Left: in a cell with high factor A.  Right: in a cell 
with low factor A. Top, all sites open. Bottom, with closed chromatin (horizontal gray) limiting 
access to a block of sites as indicated. Sizes of triangles approximate relative levels of occupancy.  
Bent arrows show potential impacts on target gene activation, assuming that transcription at each 
promoter depends on factor A binding to the neighboring site. Question mark: uncertain regulatory 
impact of low-level occupancy. 
(B) Combinatorial action via direct binding collaboration: shows impact of binding of factor A to 
higher and lower affinity sites (as in panel A) with a second factor, B (yellow ovals). Left genomic 
region, hypothetical sites where genomic sequences allow independent binding of A. Right genomic 
region, different hypothetical sites where A site binding depends on interaction of A with another 
partner (sites with light blue outlines). Here, juxtaposed sites for A and B allow highly enhanced 
binding of A, but only if B is present. As shown in diagram, impact of factor B on binding of A is 
often greatest at sites where the affinity of A for the site is otherwise low (lighter blue). Question 
mark: uncertain ability of site affinity alone to overcome requirement for partner. 
(C) Combinatorial action via local chromatin opening: shows impact on binding of factor A to 
closed sites when factor B acts as a pioneer. In this example, A is blocked by closed chromatin but B 
is not. Top: comparison of open and closed binding site occupancies by A. Bottom: zoom-in to show 
effect of B on the closed sites specifically (assuming no change in the open sites). Note that advent 
and binding of factor B creates an island of sharply localized chromatin access for A, where binding 
of A is not necessarily based on affinity of A for the site itself. 
(D) Chromatin domain opening: shows impact on factor A binding to multiple sites in an extended 
region (under “closed chromatin” bar at left) when factor B binding can catalyze broad opening of a 











Figure 2.  Hematopoiesis and gene regulatory network circuits for conditional TF action.  
(A) A simplified overview of hematopoiesis in young adult mice. Hematopoietic stem cells (HSC) 
give rise to functionally heterogeneous multipotent progenitors (MPP), which proliferate to generate 
mixed populations of partially lineage-restricted progenitors as shown, which in turn proliferate and 
then undergo stereotyped terminal differentiation into the mature cell types. Not all intermediates 
are shown. Importantly, single HSC, MPP, and partially restricted progenitor cells are individually 
capable of giving rise to diverse cell types in their clonal progeny. Lineage decisions in different 
pathways are made roughly in parallel. It is likely that some initial branches of differentiation are 
chosen probabilistically, and the choices that generate different types of partially restricted 
intermediates appear to be variable from one HSC or MPP clone to another (dashed arrows). Thus, 
strictly binary branches are not shown.  However, differentiation appears to be unidirectional for all 
hematopoietic cell types, and the terminal programs that generate output cells are canonical and 
well-defined. The requirement for certain key TFs, shown in the figure, is shared among certain 
groups of lineage branches. Although the differentiated progeny types are very distinct, their shared 
regulatory requirements correspond well to the ability of these groups of fates to be generated from 
the same single-cell progenitors in clonal assays.  
(B) Classic mutual antagonism circuit for PU.1 and GATA1 in myeloid vs. erythroid development. 
PU.1 and GATA1 are shown to repress each other’s expression at the level of transcriptional 
repression and also to interfere with each other’s trans-activation functions via protein-level 
interference (dashed lines).  The results are mutually exclusive activation of a “myeloid” program in 
cells dominated by PU.1 or an “erythroid” program in cells dominated by GATA1. Note that 
mutual repression at the transcriptional level depends not only on PU.1 and GATA1 but also on 
their respective partners, C/EBPα and FOG1 (product of Zfpm1). Shown is an updated model from 
refs. cited in the text.   
(C) Ability of PU.1 and GATA1 to collaborate for mast cell development and gene regulation. Mast 
cell development, an alternative to both erythroid and myeloid pathways, results from the moderate 
levels of expression of PU.1 and GATA1 combined with the absence of both C/EBPα and FOG1, 
as described in the text.  Here, myeloid and erythroid roles of these factors are attenuated or absent 
(dotted lines), while the distinct mast-cell program genes are activated by combinatorial activity of 
PU.1 and GATA1 (or GATA2) binding (solid lines). While myeloid and erythroid genes might still 
be engaged by PU.1 and GATA1, they are not efficiently activated in mast cells, possibly due to the 










Figure 3. Early T cell development and binding behavior of pro-T cell transcription factors 
(A) The pro-T cell developmental framework. Shown is the sequence of stages that each wave of 
multipotent precursors goes through in the thymus, dependent on Notch signaling, from thymic 
entry to first expression of T-cell receptor (TCR) genes. This progression in a young mouse takes 
approximately 2 weeks for each cohort of cells, with 1-2 cell cycles per day, yielding ~104 fold 
expansion. The stages shown are followed by a series of later intrathymic events in which cells 
undergo positive or negative selection on the basis of the TCR genes that they express, important for 
immune repertoire selection but outside the scope of the events described here. TSP: thymus-seeding 
progenitor. DN1 (ETP): first main intrathymic stage, ETP= “early T-cell progenitor”. DN2a: second 
stage, before commitment. DN2b: third stage, after commitment. DN3: fourth stage, initiation of 
first major phase of TCR locus gene rearrangements that assemble the TCR coding gene sequences 
to determine cell’s future immunological specificity.  
(B) Zoomed-in view of the commitment transition (stages DN2a to DN2b) with dynamics of 
expression of select key TFs across this interval. The figure contrasts strongly changing TFs PU.1 
and Bcl11b with minimally changing TFs Ikaros, E2A, and Runx1+3. In addition to those shown, 
TCF1 and GATA3, T-cell specific factors first expressed in the earlier, DN1 (ETP) stage, increase 
slightly or remain constant across this interval (not shown for simplicity). NB:  Note: vertical scale 
approximates a logarithmic expression scale. 
(C) Observed patterns of engagement of PU.1 (blue triangles) in pre- and post-commitment pro-T 
cells. PU.1 expression decreases substantially during commitment, thus demonstrating a natural 
titration experiment in vivo as pro-T cells developmentally progress.  Some residual binding is seen 
after commitment because PU.1 protein is long-lived, therefore persists somewhat longer than Spi1 
(PU.1-encoding) RNA expression.  This demonstrates the way PU.1 protein levels relate to 
occupancy thresholds for different affinity classes of sites (19). Affinities of binding to motifs at 
indicated classes of binding sites, based on log-odds position weight matrix motif scores validated by 
in vitro binding (152), are shown by blue shading, and closed chromatin (here, defined by ATAC-seq 
criteria) is indicated as in Fig. 1. 
(D) Observed patterns of engagement of Bcl11b (orange triangles) in pro-T cells. Bcl11b is only 
expressed after commitment.  Note that the most common Bcl11b binding sites, including sites that 
appear to mediate Bcl11b transcriptional function, do not match the motif identified for Bcl11b 










Bcl11b binding is enriched near chromatin loop anchor sites (129), although it is also abundant 
elsewhere. 
(E) Observed patterns of engagement of Runx1 and/or Runx3 (purple triangles) in pre- and post-
commitment pro-T cells. Observed Runx binding is poorly correlated with Runx-specific motif 
“quality” based on log-odds position weight matrix scores, and so only two levels of site quality are 
shown for simplicity. Note that regardless of presumed affinity, many Runx binding sites are stage 
specific, and that blocks of neighboring sites (dashed-line brackets) may become bound or unbound 
in a stage-specific way. 
 
Figure 4. Discontinuity mechanisms modulating TF action  
(A) Redeployment by “co-regulator theft” (170). Schematically shown is the effect of PU.1 (blue, 
upward-pointing triangles) on binding choices of Runx1 (magenta, downward-pointing triangles) at 
sites in a hypothetical genomic region.  Top, schematic of Runx binding without PU.1, in a post-
commitment T-cell precursor. Asterisks, theft-sensitive sites.  Bottom, Runx binding when PU.1 is 
introduced (cyan, upward-pointing triangles).  
(B) PU.1 and Runx binding to the extended Bcl11b regulatory region before and after commitment. 
Major peaks of binding are shown across ~1.7 Mb of mouse chromosome 12, traced manually from 
data shown in ref (7). Arrows: direction and extent of transcription units (partial map). Note the 
absence of Runx binding signals (magenta) across this region before commitment, despite the equal 
presence of Runx factors before and after commitment and the readily detectable binding of PU.1 
(cyan). PU.1 is not shown after commitment because its expression is strongly reduced. 
(C) Functional evidence for kinetic impact of closed chromatin at the Bcl11b regulatory region: 
stochastic, cis-acting kinetic drag breaks synchrony between alleles in same nucleus. Summary of 
evidence from (172, 195). Left to right: DN1 (ETP) stage to DN2b stage. Bcl11b transcriptional 
activation onset occurs at variable times after the cells reach DN2a stage and correlates functionally 
with commitment. Trans-acting factors: action of GATA3, TCF1, Notch signaling, and 
Runx1+Runx3 in DN1 stage and the DN1 to DN2a transition are needed to prime locus for 
opening, although Runx factors bind inefficiently in DN1 stage (cf. panel B). For DN2a stage cells, 
Runx and Notch signaling still show regulatory impact, but GATA3 and TCF1 do not. Cis-acting 
mechanism: even when all trans-acting factor requirements are met, individual alleles of Bcl11b still 










a different color fluorescent protein. Cells transitioning from Bcl11b-off to Bcl11b-on may activate 
“Red” allele first, “Yellow” allele first, or both alleles simultaneously. Activation of either allele 
shows the latest possible time when the cell has satisfied all trans-acting requirements for Bcl11b 
activation.  However, the time between activation of the first and second alleles activated varies from 
no delay to a delay of >4 days (approx 7 cell cycles), in different individual clones of DN2a cells, 
showing that the activation process depends on a slow step that can persistently distinguish the two 
alleles of the same responding gene across multiple cell cycles. In the most extreme case, the interval 
between the last required time of action of positive regulator GATA3 and first detectable expression 
of the later-activated allele of Bcl11b can be ~7 days. Kinetic relationships between expression of an 
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